"We have long known about the beneficial effects of respiratory-pacing on the cardiovascular system," Said Dr. Gianfranco Parati, Professor of Medicine and Director of the Second Cardiology Unit, S.Luca Hospital, Istituto Auxologico Italiano, Milan, Italy and an investigator of one of the studies. "Having a device which delivers such a therapy in the comfort of the patients' home is very promising. With just 15-minutes session twice a day, we have seen in our pilot study that patients' ejection fraction (EF), pulmonary artery pressure (PAP) and performance at the 6-minutes walk test improved significantly. In addition, we have seen a significant improvement in patients' quality of life (QOL) as reflected by a formal QOL questionnaire and by patients attesting to their ability to climb stairs, carry groceries and breathe easier throughout the day and night. Personally, I was most impressed by the fact that patients were reluctant to return the devices at the end of the study."
"Since the FDA clearance of our first therapeutic device, RESPeRATE to lower blood pressure, we are constantly perusing additional applications for our Low-Frequency Respiratory-Pacing technology" said Erez Gavish, CEO of InterCure, inTone's & RESPeRATE's manufacturer. "We are encouraged by the promising outcomes of these first two heart failure studies and are looking forward to study inTone further in a pivotal trial setting in the near future."